Results 151 to 160 of about 208,301 (303)

Disrupting the KRAS-SOS1 protein-protein interaction: mechanistic rationale for pan-KRAS pathway suppression and combination therapy. [PDF]

Front Chem
Kamel EM, Khadrawy SM, Ali MAM, Abukhadra MR, Yassin NYS, Alkhedhairi S, Aba Alkhayl FF, Lamsabhi AM.   +7 more
europepmc   +1 more source

Key Considerations for Targeting <i>KRAS</i> in Pancreatic Cancer: Potential Impact on the Treatment Paradigm. [PDF]

Drug Des Devel Ther
Eslinger C, Sonbol MB, George B, Babiker H, Borad MJ, Bekaii-Saab TS.   +5 more
europepmc   +1 more source

Gene signatures characterizing driver mutations in lung squamous carcinoma are predictive of the progression of pre‐cancer lesions

International Journal of Cancer, EarlyView.
What's New? Lung squamous cell carcinoma (LUSC) is more aggressive than lung adenocarcinoma, and is most often diagnosed at an advanced stage. Here, the authors evaluated gene expression data from LUSC tumors and came up with gene signatures for 34 genetic abnormalities whose expression changes throughout different precancerous stages. Several of these
Yupei Lin, Venugopalareddy Mekala, Jianrong Li, Xiang Wang, Muhammad Aminu, Jia Wu, Jianjun Zhang, Robert Taylor Ripley, Christopher I. Amos, Chao Cheng   +9 more
wiley   +1 more source

The impact of time‐to‐recurrence on post‐recurrence mortality in stage I–III colorectal cancer: A nationwide Danish cohort study

International Journal of Cancer, EarlyView.
What's New? Colorectal cancer (CRC) recurrence is a significant threat to survival despite surgery with curative intent. The characteristics of CRC recurrence, however, remain poorly understood, challenging postoperative surveillance. This study investigated post‐recurrence mortality and associations between time‐to‐recurrence and mortality among stage
Jesper Nors, Kåre Andersson Gotschalck, Rune Erichsen, Claus Lindbjerg Andersen   +3 more
wiley   +1 more source

Lymphatic Malformations With Activating KRAS Mutations Impair Lymphatic Valve Development Through Matrix Metalloproteinases. [PDF]

Arterioscler Thromb Vasc Biol
Mastrogiacomo DM, Price A, Fu Y, Banerjee R, Knauer LA, Li K, Yang Y, Davis GE, Dellinger MT, Scallan JP.   +9 more
europepmc   +1 more source

KRAS Mutation [PDF]

The Journal of Molecular Diagnostics, 2010
Wilbur A. Franklin, Jerry Haney, Michio Sugita, Lynne Bemis, Antonio Jimeno, Wells A. Messersmith   +5 more
openaire   +1 more source

Impact of non‐genetic heterogeneity of BRAF‐mutant colon cancer organoids on growth kinetics, drug sensitivity and Wnt dynamics

International Journal of Cancer, EarlyView.
What's New? Patient‐derived organoids (PDOs) model tumor biology and drug response while preserving key tumor features, yet the impact of non‐genetic culture variables is poorly understood. This study examined the influence of organoid size, seeding density, and morphology on growth, drug sensitivity, and Wnt signaling in a colorectal cancer organoid ...
Viktoria Zieger, Ellen Woehr, Jasmin Traichel, Tilman Brummer, Roland Zengerle, Sabrina Kartmann, Stefan Zimmermann   +6 more
wiley   +1 more source

Contemporary Pastoral Activities For the Sake of Humanity, And Peace. Report of the Chaplain of the President of the Republic of Poland

The Person and the Challenges
Zbigniew Kras
doaj   +1 more source

Advances in the Genetics and Molecular Biology of Brain Arteriovenous Malformations. [PDF]

Transl Stroke Res
Tsuchiya T, Miyawaki S, Ono H, Hongo H, Ogawa S, Sakai Y, Hirano Y, Sato D, Hirata S, Koizumi S, Saito N.   +10 more
europepmc   +1 more source

Prediction of the individual risk for the development of brain metastases in patients with non‐oncogene‐addicted non‐small cell lung cancer: Real‐world data from the German prospective CRISP registry (AIO‐TRK‐0315)

International Journal of Cancer, EarlyView.
What's New? Estimating the risk of developing brain metastases may enable earlier diagnosis and treatment, potentially reducing morbidity and mortality. Using the prospective CRISP lung cancer registry, the authors developed and validated a point‐based classifier for the risk of developing first brain metastases in patients with advanced or metastatic ...
Fabian Acker, Katharina Wenger, Martin Reck, Cornelius F. Waller, Petra Hoffknecht, Andre Bethge, Arnd Nusch, Marcel Reiser, Christiane Bernhardt, Michael Bendel, Carolin Lennartz, Annette Fleitz, Martina Jänicke, Paula Ludwig, Annika Groth, Frank Griesinger, Michael Thomas, Wilfried E. E. Eberhardt, Martin Sebastian, for the CRISP Registry Group   +19 more
wiley   +1 more source